PINE BROOK, N.J.and HYDERABAD, India — Alvogen and Natco Pharma on Monday announced the launch of their generic of Tamiflu (oseltamivir phosphate) capsules, the first generic of the flu treatment to hit the U.S. market. The generic was approved by the Food and Drug Administration in August.
The launch of oseltamivir phosphate is great news for U.S. patients, who will finally have access to a more affordable alternative to Tamiflu. It is also an important milestone for our U.S. business. The launch demonstrates our ability to move quickly and we are proud to partner with Natco to bring this product to market.”
The drug had U.S. sales of about $403 million for the 12 months ending December 2015, according to QuintilesIMS data.